Have a feature idea you'd love to see implemented?
Let us know!
HRTX Heron Therapeutics Inc
Price (delayed)
$1.78
Market cap
$269.97M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.3
Enterprise value
$430.3M
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron
Highlights
Heron Therapeutics's EPS has surged by 73% YoY and by 49% QoQ
HRTX's gross profit has surged by 67% year-on-year and by 18% since the previous quarter
The quick ratio has grown by 39% YoY but it has contracted by 3.3% from the previous quarter
The equity has declined by 12% since the previous quarter but it is up by 3.4% year-on-year
The debt is up by 14% year-on-year
Key stats
What are the main financial stats of HRTX
Market
Valuations
Earnings
Shares outstanding
151.67M
Market cap
$269.97M
Enterprise value
$430.3M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.16
Revenue
$136.36M
EBIT
-$47.62M
EBITDA
-$44.85M
Free cash flow
-$22.51M
Per share
Balance sheet
Liquidity
EPS
-$0.3
Free cash flow per share
-$0.15
Book value per share
-$0.25
Revenue per share
$0.9
TBVPS
$1.43
Total assets
$218.14M
Total liabilities
$256.08M
Debt
$178.71M
Equity
-$37.94M
Working capital
$110.85M
Debt to equity
-4.71
Current ratio
2.38
Quick ratio
1.76
Net debt/EBITDA
-3.57
Margins
Efficiency
Dividend
EBITDA margin
-32.9%
Gross margin
65.5%
Net margin
-35.3%
Operating margin
-34%
Return on assets
-21.7%
Return on equity
N/A
Return on invested capital
-16%
Return on capital employed
-34.6%
Return on sales
-34.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
HRTX stock price
How has the Heron Therapeutics stock price performed over time
Intraday
-1.11%
1 week
-2.2%
1 month
-9.18%
1 year
184.07%
YTD
4.71%
QTD
-10.55%
Financial performance
How have Heron Therapeutics's revenue and profit performed over time
Revenue
$136.36M
Gross profit
$89.31M
Operating income
-$46.39M
Net income
-$48.13M
Gross margin
65.5%
Net margin
-35.3%
HRTX's operating margin has surged by 71% year-on-year and by 45% since the previous quarter
The net margin has soared by 70% year-on-year and by 42% since the previous quarter
HRTX's gross profit has surged by 67% year-on-year and by 18% since the previous quarter
The operating income has surged by 66% year-on-year and by 44% since the previous quarter
Growth
What is Heron Therapeutics's growth rate over time
Valuation
What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.16
Heron Therapeutics's EPS has surged by 73% YoY and by 49% QoQ
The equity has declined by 12% since the previous quarter but it is up by 3.4% year-on-year
HRTX's price to sales (P/S) is 76% less than its 5-year quarterly average of 8.2 and 20% less than its last 4 quarters average of 2.5
HRTX's revenue is up by 16% year-on-year and by 3.2% since the previous quarter
Efficiency
How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has surged by 70% YoY and by 43% QoQ
The ROIC has soared by 67% YoY and by 43% from the previous quarter
HRTX's ROA has soared by 62% YoY and by 42% QoQ
Dividends
What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for HRTX.
Financial health
How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 15% lower than its total liabilities
The quick ratio has grown by 39% YoY but it has contracted by 3.3% from the previous quarter
The current ratio has grown by 25% YoY but it has contracted by 3.6% from the previous quarter
The debt to equity has declined by 19% year-on-year but it is up by 11% since the previous quarter
The debt is up by 14% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.